Testing for loss of response could shape future IBD care

ORLANDO — Adding genetic testing to the management of patients with inflammatory bowel disease may present an opportunity to determine which patients are at greater risk for loss of response and help select the best therapies for each individual patient, according to an expert.Jami Ann Rothe Kinnucan, MD, of Michigan Medicine, told Healio Gastroenterology and Liver Disease that identifying potential for loss of response is critical.“Patients with inflammatory bowel disease, both Crohn’s and ulcerative colitis, have an increased risk for loss of response to their anti-TNF therapy,”Read More